Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2, 2018. The report discloses the granting of Conditional Share Awards to Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) on March 1, 2018, under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation transactions.
| Recipient | Position | Instrument | Volume | Price |
|---|---|---|---|---|
| Ms E Walmsley | Chief Executive Officer | Ordinary Shares | 58,889 | £13.072 |
| Mr R Connor | President, Global Manufacturing & Supply | Ordinary Shares | 12,476 | £13.072 |
| Mr L Debruyne | President, Global Vaccines | Ordinary Shares | 18,687 | £13.072 |
| Mr S Dingemans | Chief Financial Officer | Ordinary Shares | 41,674 | £13.072 |
| Mr N Hirons | SVP, Global Ethics and Compliance | Ordinary Shares | 6,543 | £13.072 |
| Mr L Miels | President, Global Pharmaceuticals | Ordinary Shares | 11,848 | £13.072 |
| Mr B McNamara | CEO, GSK Consumer Healthcare | ADSs | 6,320 | $36.31 |
| Mr D Redfern | Chief Strategy Officer | Ordinary Shares | 12,110 | £13.072 |
| Ms C Thomas | SVP, Human Resources | Ordinary Shares | 13,163 | £13.072 |
| Mr P Thomson | President, Global Affairs | Ordinary Shares | 8,193 | £13.072 |
| Ms K Terrell | Chief Digital & Technology Officer | ADSs | 2,137 | $36.31 |
| Mr D Troy | SVP & General Counsel | ADSs | 7,349 | $36.31 |
| Dr P Vallance | Outgoing President, R&D | Ordinary Shares | 43,111 | £13.072 |
Material Changes
The filing notes a structural change to the compensation plan effective from 2018: DABP Matching Awards are no longer granted. Additionally, the filing identifies Dr. P Vallance as the "Outgoing President, R&D," indicating a leadership transition.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on business performance, or specific risk factors. It is a transaction notification regarding executive equity awards.
- Deferral Requirements: Executive Directors must defer 50% of earned bonuses into shares/ADSs for three years; other participants must defer 25%.
- Instrument Type: Awards are conditional awards over ADSs for US participants and nil-cost options over Ordinary Shares for others.
- Dividends: Share volumes listed are exclusive of dividend reinvestment accruing during the deferral period.
Investor Verification Checklist
- Verify the total number of shares/ADSs granted to ensure alignment with the company's equity compensation plan limits.
- Confirm the market price of GSK Ordinary Shares and ADSs on March 1, 2018, to validate the transaction values (£13.072 and $36.31).
- Review the 2017 Deferred Annual Bonus Plan (DABP) rules to confirm the cessation of Matching Awards.
- Monitor the status of Dr. P Vallance's departure and the appointment of a successor for the R&D division.